Enliven: Immunology and Immunotechniques is an Open access, peer reviewed international journal and it aims to publish different types of articles on emerging developments and supports current and upcoming research in the field of immunology. This journal also allows articles on immunotechniques.
This journal will support the budding scientists, scholars, academicians, researchers, and students by providing Open access platform for publishing their work.
This journal will follow the peer review policies and will bode Open access in having quality research output.
This journal combines the innovative scientific ideas and ways in immunology, immunotechniques and all other related disciplines to have an innovative output.
Enliven: Immunology and Immunotechniques invites articles from authors and we assure authors that articles received will be processed with the best policies and will disseminate the articles to the right field.
Enliven: Immunology and Immunotechniques disseminate the research findings in Cellular and Clinical Immunological aspects such as Cancer immunology, Transplantation immunology, innate immunology, vaccine development, cancer immunotherapy, allergy immunology, immunomodulation, Multiple sclerosis, Systemic lupus erythmatosus, immunology, immunoinformatics, immunogenicity of Biopharmaceuticals, and all other related areas.
On 11 & 12 June 2018, Paris will host the BioTech Pharma Summit: Gut-Brain Axis 2018 conference. This year’s event brings together leading scientists, physicians, and senior leaders to explore the human immune system and its engagement with the GI-nervous system axis in health and disease.
Go through: https://biotechpharmasummit.com/index.php/event/gut-brain-axis-2018/ for further details
On 10 & 11 September 2018, Tokyo (Japan), will host the BioTech Pharma Summit: Global Vaccines & Immunization 2018 conference. This year’s event brings together leading academic Scientists, Researchers, professors, Business delegates, talented student communities and research scholars to commerce and share their experiences and research conclusion about all aspects of Vaccination & Immunization research.
Go through: https://biotechpharmasummit.com/index.php/event/global-vaccines-immunization-2018/ for further details
On 12 & 13 November 2018, Dublin (Ireland) will host the BioTech Pharma Summit: Immunotherapy 2018 conference. This year’s event will bring together established Pharma & Biotech thought-leaders, top academics and researchers, and a collection of emerging scientists exploring next-generation breakthroughs in the burgeoning area of cancer immunotherapy.
Go through: https://biotechpharmasummit.com/index.php/event/immunotherapy-2018/ for further details
On 06 & 07 December 2018, Boston (USA) will host the BioTech Pharma Summit: Neoantigen 2018 conference. This year’s event will bring together the pioneers supercharging immunotherapy and vaccine development to share key clinical data and insights from sample acquisition, all the way through to vaccine manufacturing and getting a product to market.
Go through: https://biotechpharmasummit.com/index.php/event/neoantigen-2018/ for further details
The Euroscicon is inviting for 15th International Conference and exhibition on Immunology 2018 on July 05 - 07, 2018 Vienna, Austria. The theme of this year’s meeting is Spreading the new trends in Immunology which will provide an international platform for discussion of present and future challenges in immunological techniques, future of immunology. World-leading health practitioners, educators and researchers will present cutting-edge and practical immunological techniques based upon widely accepted evidence and will introduce new and emerging research.
Date: July 05-07, 2018
Email : firstname.lastname@example.org, email@example.com
Location : Vienna, Austria
TNF? and IL-1? have Dose Dependent Effects on Differentiation of CD4+CD127-CD25highFoxP3high T cellsAuthors: Snaefridur Halldorsdottir, Una Bjarnadottir, Laufey Geirsdottir, Brynja Gunnlaugsdottir, and Bjorn Runar Ludviksson Abstract View Pdf Full Text
Augmentation of Lipopolysaccharide (lps) Receptor Expression by Interferon y Correlates with Susceptibility to lps-Induced Apoptosis in Human Monoblastic Cell Line u937Authors: Taku Kuwabara and Shinobu Imajoh-Ohmi Abstract View Pdf Full Text
The sensitivity of modifying immuno-oncology era, is anti-PD-1 or anti-PD-L1 immunotherapy in the to conventional cancer therapies.
- The sensitivity of an modulate tumor microenvironment of anti-PD(L)1, it might an impact to conventional cancer therapy (CCT).
The tumor immune microenvironment for the Implications of staging and therapeutics.
- The tumor immune microenvironment enables the recognition of new prognostic and predictive biomarkers, the evolution of novel therapeutic targets and approach.
The treatment of melanoma for Pembrolizumab to updates and perspectives.
- The aim of this evaluation was to announce the most important updates on anti-PD-1 drug pembrolizumab from ASCO (American Society of Clinical Oncology) and ESMO (European Society for Medical Oncology) 2017 Annual Meetings.
In a people who have no therapeutic or prophylactic indication for anticoagulation. Oral anticoagulation with cancer .
- The existing evidence does not show a temporality comfort from oral anticoagulation in people with cancer but recommend an grow risk for bleeding.
Genetic and experimental evidence for the involvement of the CD6 lymphocyte receptor in psoriasis.
- Psoriasis is a chronic inflammatory skin illness with a strong genetic background and is triggered by environmental factors.